Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 5 March 2021, 16:51 HKT/SGT

Source: Eisai
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 15th International Conference on Alzheimer's and Parkinson's Disease

TOKYO, Mar 5, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest data from its Alzheimer's disease (AD) and dementia pipeline, including the investigational anti-amyloid beta (Aß) protofibril antibody lecanemab (Development Code: BAN2401), will be presented at the 15th International Conference on Alzheimer's and Parkinson's Disease (AD/PD2021) to be held virtually from March 9 to 14, 2021.

Regarding lecanemab, preliminary analysis results of changes in brain-Aß amounts as observed in subjects of the ongoing open-label extension (OLE) of the Phase II study (Study 201) will be presented orally.

Regarding aducanumab, for which applications are currently underway in the U.S., Europe and Japan, Biogen Inc. will conduct presentations on the correlation of amyloid PET and cerebrospinal fluid (CSF) biomarkers in the Phase III studies (EMERGE/ENGAGE), as well as evaluations of the safety and efficacy of aducanumab in early AD. Lecanemab and aducanumab are being jointly developed by Eisai and Biogen.

Additionally, regarding the joint research effort with Sysmex Corporation for creation of simplified diagnosis of Alzheimer's disease (AD) using blood, a presentation is planned on new data regarding prediction of amyloid positivity through plasma Aß ratio measurement on a fully automated immunoassay incorporating APOE4 status, HISCLTM*.

In addition to presenting the latest data, Eisai and Biogen are planning to host a symposium focusing on the role of Aß in the AD pathology, entitled "The Science Behind the Aß Pathway in AD". Dr. Jeffrey Cummings, Dr. John Hardy, Dr. Colin Masters, and Dr. Philip Schelten, four renowned faculty in this field, will provide a discussion about the loss of Aß homeostasis as an early pathophysiological event within the AD continuum, along with a state-of-the-art presentation on the in vivo biomarkers of Aß.

Eisai aims to realize the prevention and cure of dementia through a multi-dimensional and holistic approach with a foundation of over 35 years of experience of drug discovery activities in the area of AD and dementia. Eisai strives to create innovative medicines as soon as possible to further contribute to addressing the unmet medical needs of, as well as increasing the benefits provided to, those living with the disease and their families.

*HISCLTM is a trademark of Sysmex Corporation.

Topic: Press release summary
Source: Eisai

Sectors: BioTech
From the Asia Corporate News Network

Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Apr 23, 2021 08:07 HKT/SGT
Notice Regarding Biogen's Disclosure About the Submission of Marketing Authorization Applications in Brazil, Canada, Australia, and Switzerland for Aducanumab for Alzheimer's Disease
Apr 20, 2021 08:23 HKT/SGT
Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease
Apr 14, 2021 12:49 HKT/SGT
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting
Apr 12, 2021 12:16 HKT/SGT
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021
Mar 31, 2021 20:22 HKT/SGT
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries
Mar 31, 2021 20:18 HKT/SGT
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan
Mar 30, 2021 11:42 HKT/SGT
Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab
Mar 26, 2021 08:16 HKT/SGT
Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021
Mar 23, 2021 17:34 HKT/SGT
Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan
Mar 22, 2021 12:13 HKT/SGT
Eisai Begins Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan
More news >>
 News Alerts
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: